Same drug, same injection, different label on the box, different answer from the insurer
NHS England rolled out tirzepatide for weight management in cohorts after NICE TA1026 in December 2024: 3 Cohort 1 (from June 2025): adults with a body mass index (BMI) of 40 or higher and at least four of five weight-related conditions (type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease)
Coverage for medications such as semaglutide varies widely by plan, employer benefits, and medical necessity criteria
Reduces inflammation and irritation
Get Started $99 membership + medication cost Brand-name injection Availability, cost, and delivery timing are reviewed before prescribing